Dr Dean Tsao, chairman and CEO of PlexBio Co., Ltd., shares the story of his impressive expert background which led him to form the in vitro diagnostics (IVD) company in 2010. Dr. Tsao goes on to explain the company’s unique multiplexing technology based on the πCode™ MicroDisc (‘pi-Code MicroDiscs’), and its ability to serve as a more convenient, consistent, and cost-effective alternative to next generation sequencing (NGS) in the space of precision medicine and cancer management.
We firmly believe that by putting high complexity molecular information at the focus of disease management, PlexBio will help transform the delivery of care for patients.
